These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

967 related items for PubMed ID: 12931340

  • 1. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y, Kiyono H.
    Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
    [Abstract] [Full Text] [Related]

  • 2. New perspectives in vaccine development: mucosal immunity to infections.
    McGhee JR, Kiyono H.
    Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
    [Abstract] [Full Text] [Related]

  • 3. New perspectives in mucosal immunity with emphasis on vaccine development.
    McGhee JR, Fujihashi K, Xu-Amano J, Jackson RJ, Elson CO, Beagley KW, Kiyono H.
    Semin Hematol; 1993 Oct; 30(4 Suppl 4):3-12; discussion 13-5. PubMed ID: 8303308
    [Abstract] [Full Text] [Related]

  • 4. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.
    Immunol Lett; 2005 Mar 15; 97(2):181-8. PubMed ID: 15752556
    [Abstract] [Full Text] [Related]

  • 5. Strategies for the induction of immune responses at mucosal surfaces making use of cholera toxin B subunit as immunogen, carrier, and adjuvant.
    Holmgren J, Czerkinsky C, Lycke N, Svennerholm AM.
    Am J Trop Med Hyg; 1994 Mar 15; 50(5 Suppl):42-54. PubMed ID: 8203723
    [Abstract] [Full Text] [Related]

  • 6. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
    Mestecky J, Michalek SM, Moldoveanu Z, Russell MW.
    Behring Inst Mitt; 1997 Feb 15; (98):33-43. PubMed ID: 9382757
    [Abstract] [Full Text] [Related]

  • 7. Non-toxic Stx derivatives from Escherichia coli possess adjuvant activity for mucosal immunity.
    Ohmura-Hoshino M, Yamamoto M, Yuki Y, Takeda Y, Kiyono H.
    Vaccine; 2004 Sep 09; 22(27-28):3751-61. PubMed ID: 15315856
    [Abstract] [Full Text] [Related]

  • 8. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 09; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 9. Nasopharyngeal-associated lymphoreticular tissue (NALT) immunity: fimbriae-specific Th1 and Th2 cell-regulated IgA responses for the inhibition of bacterial attachment to epithelial cells and subsequent inflammatory cytokine production.
    Yanagita M, Hiroi T, Kitagaki N, Hamada S, Ito HO, Shimauchi H, Murakami S, Okada H, Kiyono H.
    J Immunol; 1999 Mar 15; 162(6):3559-65. PubMed ID: 10092814
    [Abstract] [Full Text] [Related]

  • 10. Live varicella vaccine polarizes the mucosal adjuvant action of cholera toxin or its B subunit on specific Th1-type helper T cells with a single nasal coadministration in mice.
    Sasaki K, Kato M, Takahashi T, Ochi S, Ichinose Y, Shiraki K, Asano Y, Iwanaga M, Tsuji T.
    J Med Virol; 2003 Jun 15; 70(2):329-35. PubMed ID: 12696126
    [Abstract] [Full Text] [Related]

  • 11. A new intranasal influenza vaccine based on a novel polycationic lipid--ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice.
    Joseph A, Itskovitz-Cooper N, Samira S, Flasterstein O, Eliyahu H, Simberg D, Goldwaser I, Barenholz Y, Kedar E.
    Vaccine; 2006 May 01; 24(18):3990-4006. PubMed ID: 16516356
    [Abstract] [Full Text] [Related]

  • 12. The use of a mutant TNF-alpha as a vaccine adjuvant for the induction of mucosal immune responses.
    Kayamuro H, Abe Y, Yoshioka Y, Katayama K, Nomura T, Yoshida T, Yamashita K, Yoshikawa T, Kawai Y, Mayumi T, Hiroi T, Itoh N, Nagano K, Kamada H, Tsunoda S, Tsutsumi Y.
    Biomaterials; 2009 Oct 01; 30(29):5869-76. PubMed ID: 19646748
    [Abstract] [Full Text] [Related]

  • 13. Immunity in response to particulate antigen-delivery systems.
    Storni T, Kündig TM, Senti G, Johansen P.
    Adv Drug Deliv Rev; 2005 Jan 10; 57(3):333-55. PubMed ID: 15560945
    [Abstract] [Full Text] [Related]

  • 14. Starch microparticles as a vaccine adjuvant: only uptake in Peyer's patches decides the profile of the immune response.
    Stertman L, Lundgren E, Sjöholm I.
    Vaccine; 2006 Apr 24; 24(17):3661-8. PubMed ID: 16513226
    [Abstract] [Full Text] [Related]

  • 15. [Current progress in the development of mucosal vaccines].
    Takeyama N, Yuki Y, Kiyono H.
    Nihon Rinsho; 2011 Sep 24; 69(9):1555-60. PubMed ID: 21922752
    [Abstract] [Full Text] [Related]

  • 16. In defense of mucosal surfaces. Development of novel vaccines for IgA responses protective at the portals of entry of microbial pathogens.
    McGhee JR, Mestecky J.
    Infect Dis Clin North Am; 1990 Jun 24; 4(2):315-41. PubMed ID: 2189002
    [Abstract] [Full Text] [Related]

  • 17. Immunostimulatory sequence oligodeoxynucleotide: A novel mucosal adjuvant.
    Horner AA, Raz E.
    Clin Immunol; 2000 Apr 24; 95(1 Pt 2):S19-29. PubMed ID: 10729234
    [Abstract] [Full Text] [Related]

  • 18. Mucosal immune network in the gut for the control of infectious diseases.
    Iijima H, Takahashi I, Kiyono H.
    Rev Med Virol; 2001 Apr 24; 11(2):117-33. PubMed ID: 11262530
    [Abstract] [Full Text] [Related]

  • 19. Involvement of dendritic cell subsets in the induction of oral tolerance and immunity.
    Fleeton M, Contractor N, Leon F, He J, Wetzel D, Dermody T, Iwasaki A, Kelsall B.
    Ann N Y Acad Sci; 2004 Dec 24; 1029():60-5. PubMed ID: 15681744
    [Abstract] [Full Text] [Related]

  • 20. Mucosal immunization using recombinant plant-based oral vaccines.
    Streatfield SJ.
    Methods; 2006 Feb 24; 38(2):150-7. PubMed ID: 16431131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 49.